STOCK TITAN

Tandem Diabetes Care gets FDA clearance for tubeless Mobi

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Tandem Diabetes Care, Inc. received U.S. FDA 510(k) clearance on November 12, 2026, for Tandem Mobi to support both tubed and tubeless insulin infusion. A new tubeless cartridge and infusion set convert the current pump to a tubeless device while retaining Control-IQ+ advanced hybrid closed-loop technology. The infusion set is cleared for up to 7 days of wear, and the cartridge is cleared for 3 days of use. Tandem said the configuration can help simplify diabetes management through less frequent site changes. A full U.S. commercial launch of the new cartridge and infusion set is planned for the first half of 2027.

Positive

  • Minor pointFDA 510(k) clearance covers infusion-set wear up to 7 days.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Infusion-set wear duration Up to 7 days Tubeless infusion set cleared for wear
Cartridge use duration 3 days Cartridge cleared for use
510(k) clearance regulatory
"received 510(k) clearance from the U.S. Food and Drug Administration"
A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.
automated insulin delivery system medical
"tubeless automated insulin delivery system with up to 7 days of wear"
An automated insulin delivery system is a device that automatically monitors blood sugar levels and adjusts insulin delivery without needing manual input. Think of it as a smart thermostat that keeps a room’s temperature just right, ensuring stable levels. For investors, such systems represent advances in healthcare technology that can improve quality of life and potentially reduce long-term medical costs.
hybrid closed-loop technology medical
"Control-IQ+ advanced hybrid closed-loop technology"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What options did the FDA clear for Tandem Mobi (TNDM)?

The FDA cleared Tandem Mobi for both tubed and tubeless insulin infusion options. A new tubeless cartridge and infusion set convert the current pump to a tubeless device while retaining Control-IQ+ advanced hybrid closed-loop technology.

When is Tandem Mobi Tubeless expected to launch in the United States?

Tandem plans a full commercial launch of the new tubeless cartridge and infusion set in the United States in the first half of 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001438133FALSE00014381332026-11-122026-11-12


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

____________________________
FORM 8-K
____________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 12, 2026
____________________________
Tandem Diabetes Care, Inc.
(Exact name of registrant as specified in its charter)
____________________________
Delaware001-3618920-4327508
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
 Identification No.)
12400 High Bluff Drive92130
San Diego California
(Zip Code)
(Address of principal executive offices)
Registrant’s telephone number, including area code: (858) 366-6900
N/A
(Former name or former address, if changed since last report)
____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading SymbolName of Each Exchange on Which Registered
Common Stock, par value $0.001 per shareTNDMNASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
____________________________





Item 8.01 Other Events.

On November 12, 2026, Tandem Diabetes Care, Inc. (the “Company”) received 510(k) clearance from the U.S. Food and Drug Administration for Tandem Mobi, the world’s first and only tubeless automated insulin delivery system with up to 7 days of wear (1). A new Tandem Mobi tubeless cartridge and infusion set converts the current Tandem Mobi pump into a tubeless device that can help simplify diabetes management with less frequent site changes, while offering the life-changing benefits of Control-IQ+ advanced hybrid closed-loop technology. The Tandem Mobi insulin pump is now cleared for tubeless and tubed insulin infusion options, making it the only pump that offers users the flexibility to choose the wear option that best meets their needs. Full commercial launch of the new tubeless cartridge and infusion set for Tandem Mobi is planned for the first half of 2027 in the United States.

(1) Tubeless infusion set is cleared for up to 7 days of wear. Cartridge is cleared for 3 days of use.

Forward-Looking Statements

This report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding the Company’s plans and timing for launching Tandem Mobi Tubeless. These forward-looking statements are subject to numerous risks and uncertainties, including risks related to the potential safety and other complications from the Company’s pumps and associated technologies; the ability to maintain regulatory clearance for the Company’s products; supply and manufacturing risks, including those associated with scale-up activities; the scope, progress and expansion of developing and commercializing the Company’s products; the size and growth of the market for the Company’s products compared to competitor products; the Company’s ability to protect its intellectual property; the impact of government laws, regulations and policies; and other risks identified under the “Risk Factors” heading in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, as filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. Actual results could differ materially from those anticipated or projected in the forward-looking statements. The Company undertakes no obligation to update or review any forward-looking statement in this report because of new information, future events or other factors except as required by law.
2



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Tandem Diabetes Care, Inc.
By:/s/ SHANNON M. HANSEN
Shannon M. Hansen
Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary
Date: November 13, 2026
3

Filing Exhibits & Attachments

3 documents

Keep reading